Melinta Therapeutics Competitors

Wellness Center USA (OTCMKTS:WCUI) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by insiders. Comparatively, 60.3% of Melinta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Wellness Center USA and Melinta Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Wellness Center USA and Melinta Therapeutics, as provided by MarketBeat.com.

Earnings & Valuation

This table compares Wellness Center USA and Melinta Therapeutics' revenue, earnings per share and valuation.

Wellness Center USA has higher earnings, but lower revenue than Melinta Therapeutics.

Intellipharmaceutics International (OTCMKTS:IPCIF) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Intellipharmaceutics International and Melinta Therapeutics' revenue, earnings per share and valuation.

Intellipharmaceutics International has higher earnings, but lower revenue than Melinta Therapeutics.

Profitability

This table compares Intellipharmaceutics International and Melinta Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Intellipharmaceutics International and Melinta Therapeutics, as provided by MarketBeat.com.

Summary

Melinta Therapeutics beats Intellipharmaceutics International on 3 of the 5 factors compared between the two stocks.

BriaCell Therapeutics (OTCMKTS:BCTXF) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Profitability

This table compares BriaCell Therapeutics and Melinta Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares BriaCell Therapeutics and Melinta Therapeutics' top-line revenue, earnings per share and valuation.

BriaCell Therapeutics has higher earnings, but lower revenue than Melinta Therapeutics.

Insider and Institutional Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 60.3% of Melinta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BriaCell Therapeutics and Melinta Therapeutics, as provided by MarketBeat.com.

Summary

Melinta Therapeutics beats BriaCell Therapeutics on 3 of the 5 factors compared between the two stocks.

Melinta Therapeutics (OTCMKTS:MLNTQ) and FutureWorld (OTCMKTS:FWDG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Melinta Therapeutics and FutureWorld's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Melinta Therapeutics and FutureWorld's top-line revenue, earnings per share (EPS) and valuation.

FutureWorld has lower revenue, but higher earnings than Melinta Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Melinta Therapeutics and FutureWorld, as provided by MarketBeat.com.

Summary

Melinta Therapeutics beats FutureWorld on 1 of the 1 factors compared between the two stocks.

Melinta Therapeutics (OTCMKTS:MLNTQ) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Melinta Therapeutics and International Stem Cell's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Melinta Therapeutics and International Stem Cell's top-line revenue, earnings per share (EPS) and valuation.

International Stem Cell has lower revenue, but higher earnings than Melinta Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Melinta Therapeutics and International Stem Cell, as provided by MarketBeat.com.

Summary

Melinta Therapeutics beats International Stem Cell on 3 of the 5 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Insider & Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by insiders. Comparatively, 60.3% of Melinta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amarantus BioScience and Melinta Therapeutics, as provided by MarketBeat.com.

Profitability

This table compares Amarantus BioScience and Melinta Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Amarantus BioScience and Melinta Therapeutics' top-line revenue, earnings per share and valuation.

Amarantus BioScience has higher earnings, but lower revenue than Melinta Therapeutics.

Summary

Melinta Therapeutics beats Amarantus BioScience on 2 of the 3 factors compared between the two stocks.